 WOBURN, Mass., Jan. 04, 2022 GLOBE NEWSWIRE -- Replimune Group, Inc. Nasdaq: REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 7:30 AM ET. 